With a sensitivity of 96.89% (95% CI: 95.66-98.12) the multi-parametric device MHAA can effectively detect HCV infection in donors.
HCV Screening of Donors: The HCV was screened simultaneously by Abbott Architect antiHCV assay (CLIA) and Multisure HCV antibody assay (MHAA) in all the donors.
Determination of comparative efficacy of MHAA: In order to study the efficacy of MHAA; about 250 samples including both positive and negative samples by NAT were further tested using standard serological assays including ELISA by MonolisaTM Anti-HCV Plus V2 and two different EIAs i.e.
Determination of comparative efficacy of MHAA: The MHAA detected anti-HCV antibodies in 199 donors out of these 133 had active HCV infection as confirmed by NAT.
The MHAA is a third generation serological assay with multiple recombinant HCV antigens from the core, NS3, NS4 and NS5 regions and thus can be useful in overall improved detection of patients exposed to HCV even during the window period.20 It is an inexpensive simple qualitative visual rapid test and does not require sophisticated instruments, expensive reagents or time consuming protocols as compared to other tests such as ELISA and NAT.
suggest that MHAA cannot perform well with frozen samples since the results for all the frozen samples tested during their study were either negative or indeterminate.22 Thus, special care is required when using this device in case of stored samples.